ISOTRETINOIN | A205063 | ACTAVIS LABORATORIES FL INC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
CIPHER PHARMACEUTICALS, INC. et al v. WATSON LABORATORIES, INC.-FLORIDA et al 1 patentANDA 205063isotretinoin | D.N.J. | 2013-10-29 | Terminated 2015-10-30 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
Highest NADAC/Unit
$11.94
per ea
Lowest NADAC/Unit
$4.18
per ea
Brand NDCs
0
Generic NDCs
5
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 00591243315ISOTRETINOIN 10 MG CAPSULE | $11.94 | EA | Generic | — | 2026-01-21 |
| 00591245115ISOTRETINOIN 25 MG CAPSULE | $10.78 | EA | Generic | — | 2026-06-17 |
| 00591243415ISOTRETINOIN 20 MG CAPSULE | $5.97 | EA | Generic | — | 2026-06-17 |
| 00591243615ISOTRETINOIN 40 MG CAPSULE | $5.31 | EA | Generic | — | 2026-06-17 |
| 00591243515ISOTRETINOIN 30 MG CAPSULE | $4.18 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.